Deutsche Bank
SPRY icon

Deutsche Bank’s ARS Pharmaceuticals SPRY Stock Holding History

Deutsche Bank’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$528K Buy
65,866
+11,375
+21% +$97.8K ﹤0.01% 2743
2026
Q1 		$438K Buy
54,491
+5,764
+12% +$55.2K ﹤0.01% 2644
2025
Q4 		$568K Buy
48,727
+6,776
+16% +$65.9K ﹤0.01% 2501
2025
Q3 		$422K Buy
41,951
+4,938
+13% +$70.9K ﹤0.01% 2645
2025
Q2 		$646K Sell
37,013
-2,090
-5% -$30.2K ﹤0.01% 2323
2025
Q1 		$492K Sell
39,103
-4,274
-10% -$51.4K ﹤0.01% 2499
2024
Q4 		$458K Buy
43,377
+14,604
+51% +$205K ﹤0.01% 2657
2024
Q3 		$417K Buy
28,773
+7,987
+38% +$95K ﹤0.01% 2567
2024
Q2 		$177K Buy
20,786
+6,042
+41% +$53.6K ﹤0.01% 2870
2024
Q1 		$151K Sell
14,744
-508
-3% -$3.79K ﹤0.01% 2978
2023
Q4 		$83.6K Buy
+15,252
New +$66.8K ﹤0.01% 3300
2022
Q2 		– Sell
-11,140
Closed -$39K – 4312
2022
Q1 		$39K Sell
11,140
-1,318
-11% -$5.74K ﹤0.01% 3912
2021
Q4 		$83K Buy
12,458
+658
+6% +$5.35K ﹤0.01% 3780
2021
Q3 		$118K Buy
11,800
+4,058
+52% +$100K ﹤0.01% 3833
2021
Q2 		$239K Sell
7,742
-4,588
-37% -$147K ﹤0.01% 3683
2021
Q1 		$538K Buy
12,330
+7,330
+147% +$347K ﹤0.01% 3051
2020
Q4 		$232K Buy
+5,000
New +$167K ﹤0.01% 3388

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Deutsche Bank's SPRY Position: Q2 2026 in Review

Deutsche Bank increased its ARS Pharmaceuticals (SPRY) stake by 21% in Q2 2026, buying an estimated $97.8K and bringing the position to 65,866 shares worth $528K. The position accounts for ﹤0.01% of the portfolio, ranked #2743.

Deutsche Bank first reported a position in SPRY in Q4 2020 and has held it in 17 quarters since. The position peaked at $646K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Deutsche Bank held 65,866 shares of ARS Pharmaceuticals worth $528K as of Q2 2026.
  • Deutsche Bank bought 11,375 ARS Pharmaceuticals shares in Q2 2026, an estimated $97.8K.
  • ARS Pharmaceuticals made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #2743 holding.
  • Deutsche Bank first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 17 quarters since.
  • Deutsche Bank's ARS Pharmaceuticals position peaked at $646K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.